Originally posted by pmiguel
View Post
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
-
The grand scheme of things of for-profit sector is targeted resequencing for diagnostic. The only thing ONT are proposing that could be useful to them is the no sample prep at all. And I am having a hard time believing that.
While a $100 disposable cartridge would be nice too, especially to forensic and DTC providers, a Q14 isn't useful for any of them.
I agree with other people prediction that ONT will be the next PacBio. It's noble to claim that they will delay their launch until they get Q30, but they need investors, and the current ones will eventually want to cash in. PacBio was able to hype and overhype for 5 years. How much longer is it going to be for ONT?
Comment
-
Just a quick reminder of some facts. For ONT to be next PacBio, at least they need to show some data and publish papers in NEJM from sample to print within weeks, not once, but twice. And, they will also need to publish DNA sequencing data/DNA modification data in Nature / Nature Biotech to show important biological results that can not be resolved by 2nd gen. sequencing / Sanger sequencing, etc. (Not just nucleotide identification. DNA sequencing is not about identifying bases/short segments. DNA sequencing should be about efficiently linking long range information...) Commercially successfully or not, the publications and real data already help to reveal some new biology. Until nanopore is no longer nanovapor, there is no fair comparison.Last edited by seqnextgen; 11-16-2012, 09:11 PM.
Comment
-
Originally posted by seqnextgen View PostJust a quick reminder of some facts. For ONT to be next PacBio, at least they need to show some data and publish papers in NEJM from sample to print within weeks, not once, but twice. And, they will also need to publish DNA sequencing data/DNA modification data in Nature / Nature Biotech to show important biological results that can not be resolved by 2nd gen. sequencing / Sanger sequencing, etc. (Not just nucleotide identification. DNA sequencing is not about identifying bases/short segments. DNA sequencing should be about efficiently linking long range information...) Commercially successfully or not, the publications and real data already help to reveal some new biology. Until nanopore is no longer nanovapor, there is no fair comparison.
Comment
-
Originally posted by TonyBrooks View PostThe problem is that scaffold runs for de novo are so niche in the grand scheme of things.
I wonder what updates will come out next week at AGBT...Paul Krzyzanowski
Blog: www.checkmatescientist.net
Comment
-
Originally posted by paulk View PostNot really; I'd love to be able to quickly map out cancer genome rearrangements and a 4% error rate wouldn't bother me for that purpose.
I wonder what updates will come out next week at AGBT...
Comment
-
Originally posted by krobison View PostWhat? You weren't out on the strand digging through sand like a madman?
Comment
-
Originally posted by krobison View PostWhat? You weren't out on the strand digging through sand like a madman?
I should have been stalking the bar, apparently.
Comment
-
Originally posted by krobison View PostWhat? You weren't out on the strand digging through sand like a madman?
Comment
-
Originally posted by Clive
([urlhttp://pathogenomics.bham.ac.uk/blog/2013/03/a-chat-with-oxford-nanopores-clive-brown-at-agbt-2013[/url])
“We didn’t even know that long reads were so important to people until after that AGBT presentation.”Last edited by Jeremy; 03-06-2013, 05:41 PM.
Comment
-
Waaaaaa we made promises we couldn't keep to get attention and funding...and now people expect us to keep them!
<tiny violin playing>
Seriously though, having been through the bring up of a single molecule sequencer...if the CTO is opining in a bar to a blogger about improving consensus accuracy by throwing in multiple types of pores...they are a LONG way from finalizing a chemistry, let alone stabilizing and commercializing it.
Happy to eat words. Actually I love having my pessimism proven wrong.
And I hope I'm not off Clive's list. I could do some long range clinical haplotyping pretty easily!
Comment
-
Originally posted by ECO View PostSeriously though, having been through the bring up of a single molecule sequencer...if the CTO is opining in a bar to a blogger about improving consensus accuracy by throwing in multiple types of pores...they are a LONG way from finalizing a chemistry, let alone stabilizing and commercializing it.
Given that they are continuously screening new and better pores and that is in fact one of the cool things about a biological nanopore (just like other sequencing companies regularly screen for new polymerases), I didn't necessarily see that as reflective of where they are in the product development pipeline.
Comment
-
Originally posted by nickloman View PostGiven that they are continuously screening new and better pores and that is in fact one of the cool things about a biological nanopore (just like other sequencing companies regularly screen for new polymerases), I didn't necessarily see that as reflective of where they are in the product development pipeline.
We all hope they will stop the screening at some point and release the first product we can use.
Comment
Latest Articles
Collapse
-
by seqadmin
The field of immunogenetics explores how genetic variations influence immune responses and susceptibility to disease. In a recent SEQanswers webinar, Oscar Rodriguez, Ph.D., Postdoctoral Researcher at the University of Louisville, and Ruben Martínez Barricarte, Ph.D., Assistant Professor of Medicine at Vanderbilt University, shared recent advancements in immunogenetics. This article discusses their research on genetic variation in antibody loci, antibody production processes,...-
Channel: Articles
11-06-2024, 07:24 PM -
-
by seqadmin
Next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR) are essential techniques for investigating the genome, transcriptome, and epigenome. In many cases, choosing the appropriate technique is straightforward, but in others, it can be more challenging to determine the most effective option. A simple distinction is that smaller, more focused projects are typically better suited for qPCR, while larger, more complex datasets benefit from NGS. However,...-
Channel: Articles
10-18-2024, 07:11 AM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, 11-08-2024, 11:09 AM
|
0 responses
221 views
0 likes
|
Last Post
by seqadmin
11-08-2024, 11:09 AM
|
||
Started by seqadmin, 11-08-2024, 06:13 AM
|
0 responses
163 views
0 likes
|
Last Post
by seqadmin
11-08-2024, 06:13 AM
|
||
Started by seqadmin, 11-01-2024, 06:09 AM
|
0 responses
80 views
0 likes
|
Last Post
by seqadmin
11-01-2024, 06:09 AM
|
||
New Model Aims to Explain Polygenic Diseases by Connecting Genomic Mutations and Regulatory Networks
by seqadmin
Started by seqadmin, 10-30-2024, 05:31 AM
|
0 responses
27 views
0 likes
|
Last Post
by seqadmin
10-30-2024, 05:31 AM
|
Comment